摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-<2,3-bis-O-(tert-butyldimethylsilyl)-4α-hydroxymethyl-β-D-ribo-pentofuranosyl>uracil | 173846-42-9

中文名称
——
中文别名
——
英文名称
1-<2,3-bis-O-(tert-butyldimethylsilyl)-4α-hydroxymethyl-β-D-ribo-pentofuranosyl>uracil
英文别名
2’,3’-di-O-(tert-butyldimethylsilyl)-4’-C-(hydroxymethyl)uridine;4′-hydroxymethyl-2′,3′-bis(tert-butyldimethylsilyl)uridine;1-[(2R,3R,4S)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
1-<2,3-bis-O-(tert-butyldimethylsilyl)-4α-hydroxymethyl-β-D-ribo-pentofuranosyl>uracil化学式
CAS
173846-42-9
化学式
C22H42N2O7Si2
mdl
——
分子量
502.756
InChiKey
XNMIRTMIXCGTCN-FGTMMUONSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.14±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.57
  • 重原子数:
    33
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    118
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    1-<2,3-bis-O-(tert-butyldimethylsilyl)-4α-hydroxymethyl-β-D-ribo-pentofuranosyl>uracil 在 palladium on activated charcoal 吡啶叠氮化锂四丁基氟化铵氢气 作用下, 以 四氢呋喃甲醇N,N-二甲基甲酰胺 为溶剂, 反应 1.49h, 生成 1-4-C-aminomethyl-5-amino-β-D-erythro-pentofuranosyl uracil
    参考文献:
    名称:
    Synthesis of 4′,4′-C-diaminomethyl nucleoside derivative as a building block for constructing libraries via amide bond formation
    摘要:
    Preparation of the 4',4-C-diaminomethyl uridine analog starting from the commercial uridine via 4',4'-C-dihydroxymethyl uridine, 4',4'- C-bis-trifluoromethanesulfonyl oxymethyl uridine, and 4',4'-C-diazidomethyl uridine in total eight steps was achieved in 8% yield. Steric hindrance between 3'-O-TBDMS and 5'-O-triflate prevented the undesired ring closure which made the synthesis of target compound feasible. (c) 2007 Published by Elsevier Ltd.
    DOI:
    10.1016/j.tetlet.2007.03.002
  • 作为产物:
    参考文献:
    名称:
    核糖核苷3'-磷酸二酯的裂解和异构化过程中氨基的分子内参与:在稳定的中间体中的作用
    摘要:
    双核苷3',5'-磷酸二酯模型,5'-氨基-4'-氨基甲基-5'-脱氧尿苷3',5'-胸苷,在3'-的4'-位置结合了两个氨基甲基官能团已制备了连接的核苷,并在很宽的pH范围内研究了其水解反应。发现氨基官能团可加速质子化和中性形式的磷酸二酯键的裂解和异构化。当以质子化形式存在时,3',5'-磷酸二酯键的裂解及其异构化为2',5'-键是pH无关的,并且是uridylyl-3'相应反应的50-80倍,5'-尿苷(3',5'-UpU)。生成的2',5'-异构体的裂解也被加速,尽管比3',5'-异构体的裂解少,但是回到3',5'-二酯的异构化并没有增强。当氨基去质子化时 两种异构体的裂解反应仍然与pH无关,并且比UpU与pH无关的裂解快了1000倍。有趣的是,现在2'至3'异构化比其逆反应快得多。讨论了这些反应的机理。速率加速很大程度上是由质子化的氨基与磷烷中间体的静电和氢键相互作用引起的。
    DOI:
    10.1002/chem.201301711
点击查看最新优质反应信息

文献信息

  • Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479
    作者:David B. Smith、Joseph A. Martin、Klaus Klumpp、Stewart J. Baker、Peter A. Blomgren、Rene Devos、Caroline Granycome、Julie Hang、Christopher J. Hobbs、Wen-Rong Jiang、Carl Laxton、Sophie Le Pogam、Vincent Leveque、Han Ma、Graham Maile、John H. Merrett、Arkadius Pichota、Keshab Sarma、Mark Smith、Steven Swallow、Julian Symons、David Vesey、Isabel Najera、Nick Cammack
    DOI:10.1016/j.bmcl.2007.02.004
    日期:2007.5
    A series of 4'-substituted ribonucleoside derivatives has been prepared and evaluated for inhibition of hepatitis C virus (HCV) RNA replication in cell culture. The most potent and non-cytotoxic derivative was compound 28 (4'-azidocytidine, R1479) with an IC(50) of 1.28 microM in the HCV replicon system. The triphosphate of compound 28 was prepared and shown to be an inhibitor of RNA synthesis mediated
    制备了一系列的4'-取代核糖核苷衍生物,并评估了其在细胞培养中对丙型肝炎病毒(HCV)RNA复制的抑制作用。最有效和无细胞毒性的衍生物是化合物28(4'-叠氮吡啶,R1479),在HCV复制子系统中的IC(50)为1.28 microM。制备了化合物28的三磷酸酯,并显示出它是由NS5B(IC(50)= 320 nM)介导的RNA合成抑制剂,NS5B是HCV编码的RNA聚合酶。有关类似物的数据已被用来对这一系列核苷的活性产生一些初步的要求。
  • Nucleosides and Nucleotides. 185. Synthesis and Biological Activities of 4‘α-<i>C</i>-Branched-Chain Sugar Pyrimidine Nucleosides
    作者:Makoto Nomura、Satoshi Shuto、Motohiro Tanaka、Takuma Sasaki、Shuichi Mori、Shiro Shigeta、Akira Matsuda
    DOI:10.1021/jm990050i
    日期:1999.7.1
    4'alpha-position did not show any cytotoxicity. The antiviral activities of these nucleosides against HSV-1, HSV-2, and HIV-1 in vitro were also examined. Compounds 22 and 23 showed antiviral activities against HSV-1 and HSV-2 without showing significant toxicity to the host cells (MRC-5 cells). Although almost all of the nucleosides showed anti-HIV-1 activities, they were also cytotoxic to the host cells (MT-4)
    由2'-脱氧胞苷尿苷合成了一系列的4'α-C-支链嘧啶核苷。在2'-脱氧胞苷系列中,在4'α-位置的取代基在体外以Me(23)> CN(22)> C(symbol)CH(21)> CH =的顺序影响对L1210小鼠白血病细胞的细胞毒性。 CH(2)(19)> Et(24)> CH = CHCl(20)。然而,在4'α位具有乙炔基和基的尿苷胞苷生物没有显示出任何细胞毒性。还检查了这些核苷在体外对HSV-1,HSV-2和HIV-1的抗病毒活性。化合物22和23显示出针对HSV-1和HSV-2的抗病毒活性,而没有显示出对宿主细胞(MRC-5细胞)的明显毒性。尽管几乎所有核苷都具有抗HIV-1活性,
  • Participation of an additional 4′-hydroxymethyl group in the cleavage and isomerization of ribonucleoside 3′-phosphodiesters
    作者:Luigi Lain、Harri Lönnberg、Tuomas Lönnberg
    DOI:10.1039/c5ob00400d
    日期:——
    4′-(Hydroxymethyl)uridylyl-3′,5′-thymidine, an RNA model bearing an extra hydroxymethyl group at the 4′-position of the 3′-linked nucleoside, has been prepared and its cleavage and isomerization reactions studied over a wide pH range (from 0 to 12). Overall, the pH-rate profiles of these reactions were very similar to those of uridylyl-3′,5′-uridine (UpU) – only a very modest acceleration was observed
    制备了4'-(羟甲基)uridylyl-3',5'-胸腺嘧啶核苷(RNA模型,在3'-连接核苷的4'-位带有一个额外的羟甲基),并对其裂解和异构化反应进行了研究。 pH值范围广(从0到12)。总体而言,这些反应的pH速率曲线与uridylyl-3',5'-尿苷(UpU)的pH曲线非常相似-在酸性和中性条件下仅观察到非常适度的加速。显然,通过附加的羟甲基官能团的氢键辅助作用不显着。
  • 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    申请人:——
    公开号:US20030236216A1
    公开(公告)日:2003-12-25
    The present invention relates to the use of nucleoside derivatives of formula I 1 wherein B signifies a 9-purinyl residue B1 of formula 2 or a 1-pyrimidyl residue B2 of formula 3 wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    本发明涉及使用公式I1的核苷衍生物,其中B表示公式2的9-嘌呤基残基B1或公式3的1-嘧啶基残基B2,其中符号如规范中所定义,并且其药物可接受的盐;用于治疗由丙型肝炎病毒(HCV)介导的疾病,用于制备用于该治疗的药物以及含有这些化合物的制药组合物。
查看更多